

## DAFTAR PUSTAKA

1. Mutter GL, Prat J. 2014. Endometrial Adenocarcinoma, in: Pathology of the Female Reproductive Tract. 3<sup>rd</sup> ed. Philadelphia. Elsevier. pp 370-98.
2. Kurman RJ, Ellenson LH, Ronnet BM. 2019. Endometrial Carcinoma, in: Blaustein's Pathology of the Female Genital Track. 7<sup>th</sup> ed. Cham, Switzerland. Springer Nature. pp 473-534.
3. Lax SF. 2017. Pathology of Endometrial Carcinoma, in: Molecular Genetics of Endometrial Carcinoma. Graz, Austria. Springer International Publishing. pp 75-96.
4. Kahzaei Z, Dehkordi AH, Amiri M, et al. 2018. The Incidence and Mortality of Endometrial Cancer and Its Association with Body Mass Index and Human Development Index in Asian Population. Word Cancer Research Journal. Vol 5(4), pp 1-11.
5. Kurman RJ, Carcangiu ML, Herrington CS, et al. 2014. Tumor of the Uterine Corpus, in: WHO Classification of Tumours of Female Reproductive Organs. 4<sup>th</sup> ed. Lyon. International Agency for Research on Cancer. pp 121-54.
6. Talhouk A, McAlpine JN. 2016. New Classification of Endometrial Cancers: The Development and Potential Applications of Genomic-Based Classification in Research and Clinical Care. Gynecologic Oncology Research and Practice. Vol 3(14), pp 1-12.
7. Nakamura M, Obata T, Daikoku T, et al. 2019. The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy. International Journal of Molecular Sciences. Vol 20(5482), pp 1-16.
8. Talhouk A, McAlpine JN. 2016. New Classification of Endometrial Cancers: The Development and Potential Applications of Genomic-Based Classification in Research and Clinical Care. Gynecologic Oncology Research and Practice. Vol 3(14), pp 1-12.
9. Petrova YI, Schecterson L, Gumbiner BM. 2016. Roles for E-cadherin Cell Surface Regulation in Cancer. Molecular Biology of the Cell. Vol 27, pp 3233-44.

10. Yalta T, Atay L, Atakay F, et al. 2009. E-cadherin Expression in Endometrial Malignancies: Comparison between Endometrioid and Non-Endometrioid Carcinomas. *The Journal of International Medical Research*. Vol 37. Pp 163-8.
11. Sugihara T. 2016. Loss of Adherens Junction Protein E-cadherin is a Biomarker of High-Grade Histology and Poor Prognosis in Endometrial Cancer. *Annals of Clinical and Laboratory Research*. Vol 4(1), pp 1-5.
12. Jastania R, Nageeti T. 2018. Is p53 Overexpression a Predictor of Worse Outcome in Endometrioid Endometrial Carcinomas?. *International Journal of Pathology and Clinical Research*. Vol 4(81).
13. Koyuncuoglu M, Okyay E, Saatli B, et al. 2012. Tumor Budding and E-Cadherin Expression in Endometrial Carcinoma: Are They Prognostic Factors in Endometrial Cancer? *Gynecologic Oncology*. Vol 125, pp 208-13.
14. Xie X, Zheng X, Wang J, et al. 2017. Clinical Significance of Twist, E-cadherin and N-cadherin Protein Expression on Endometrioid Carcinoma. *Journal of Cancer Research and Therapeutics*. Vol 13(5), pp 817-22.
15. Lewczuk L, Pryczynicz A, Guzińska-Ustymowicz K. 2021. Expression Level of E-, N- and P-cadherin Proteins in Endometrial Cancer. *Oncology Letters*. Vol 21, pp 1-9.
16. Ozekinci S, Uzunlar AK, Senturk S, et al. 2010. Expression of E-cadherin, COX-2, P53 and BCL2 in Prostate Carcinomas: Correlation with Tumor Differentiation and Metastatic Potential. *Biotechnol. & Biotechnol. Eq.* Vol 24(4), pp 2112-6.
17. Park JY, Hong DG, Chong GO, et al. 2018. Tumor Budding is a Valuable Diagnostic Parameter in Prediction of Disease Progression of Endometrial Endometrioid Carcinoma. *Pathology & Oncology Research*.
18. Rodriguez AC, Blanchard Z, Maurer KA, et al. 2019. Estrogen Signaling in Endometrial Cancer: A Key Oncogenic Pathway with Several Open Questions. *Harm Cancer*. Vol 10(2-3), pp 1-22.
19. Saed L, Varse F, Baradaran HR, et al. 2019. The Effect of Diabetes on the Risk of Endometrial Cancer: An Updated Systematic Review and Meta-Analysis. *BMC Cancer*. Vol 19(527), pp 1-12.

20. Harris HR, Terry KL. 2016. Polycystic Ovary Syndrome and Risk of Endometrial, Ovarian, and Breast Cancer: A Systematic Review. *Fertility Research and Practice*. Vol 2(14), pp 1-9.
21. Bacalbasa N, Stoica C, Popa I, et al. 2015. Endometrial Carcinoma Associated with Ovarian Granulosa Cell Tumors-A Case Report. *Anticancer Research*. Vol 35, pp 5547-50.
22. Wang A, McCracken J, Li Y, et al. 2018. The Practice of Universal Screening for Lynch Syndrome in Newly Diagnosed Endometrial Carcinoma. *Health Sci Rep*. pp 1-7.
23. Hu R, Hilakivi-Clarke L, Clarke R. 2015. Molecular Mechanism of Tamoxifen-Associated Endometrial Cancer (Review). *Oncology Letters*. Vol 9, pp 1495-1501.
24. Felix AS, Yang HP, Gierach GL, et al. 2014. Cigarette Smoking and Endometrial Carcinoma Risk: The Role of Effect Modification and Tumor Heterogeneity. *Springer International Publishing*. Vol 25(4), pp 1-18.
25. Braun MM, Overbeek-Wager EA, Grumbo RJ. 2016. Diagnosis and Management of Endometrial Cancer. *American Academy of Family Physician*. Vol 93(0), pp468-74.
26. Crum CP, Quick CM, Laury AR, et al. 2016. Endometrioid Carcinoma, in: *Gynecologic and Obstetric Pathology*. 1<sup>st</sup> ed. Philadelphia. Elsevier, pp 396-9.
27. Rodriguez AC, Blanchard Z, Maurer KA, et al. 2019. Estrogen Signaling in Endometrial Cancer: A Key Oncogenic Pathway with Several Open Question. *Horm Cancer*. Vol 10 (2-3), pp 51-63.
28. Goldblum JR, Lamps LW, McKenney, et al. 2018. Endometrial Carcinoma, in: *Rosai and Ackerman's Surgical Pathology*. 11<sup>th</sup> ed. Philadelphia. Elsevier Inc. pp 1306-18.
29. de Andrade DAP, da Silva VD, Matsushita GdM, et al. 2019. Squamous Differentiation Portends Poor Prognosis in Low and Intermediate-Risk Endometrioid Endometrial Cancer. *Plos One*. Vol 10(14), pp 1-9.
30. Murali R, Davidson B, Fadare O, et al. 2018. High-Grade Endometrial Carcinoma: Morphologic and Immunohistochemical Features, Diagnostic

Challenges and Recommendations. International Society of Gynecological Pathologist. Vol 38(1), pp s40-s63.

31. Zhou F, Zhang X, Chen H, et al. 2020. Dedifferentiated Endometrioid Carcinomas with Neuroendocrine Differentiation: A Clinicopathological and Immunohistochemical Study of Three Cases. Cancer Management and Research. Vol 12, pp 11623-9.
32. Binder PS, Mutch DG. 2014. Update on Prognostic Markers for Endometrial Cancer. Womens Health. Vol 10(3), pp 277-88.
33. Coradini D, Casarsa C, Oriana S. 2011. Eithelial Cell Polarity and Tumorigenesis: New Perspective for Cancer Detection and Treatment. Acta Pharmacologica Sinica. Vol 32, pp 552-64.
34. Grigore AD, Jolly MK, Jia D, et al. 2016. Tumor Budding: The Name is EMT. Partial EMT. Journal of Clinical Medicine. Vol 5(51), pp 1-23.
35. Kumar V, Abbas AK, Aster JC. 2018. The Cell as a Unit of Health and Disease, In: Robbin's Basic Pathology. 10<sup>th</sup> ed. Philadelphia, US. Elsevier, pp 12.
36. Yu W, Yang L, Li T, et al. 2019. Cadherin Signaling in Cancer: Its Function and Role as a Therapeutic Target. Frontiers in Oncology. Vol 9 (989).
37. Gall TMH, Frampton AE. 2013. Gene of the Month: E-cadherin (CDH1). Journal of Clinical Pathology. Vol 0, pp 1-5.
38. Crum CP, Nucci MR, Howitt BE, et al. 2018. Endometrial Adenocarcinoma, in: Diagnostic Gynecologic and Obstetric Pathology. 3rd ed. Philadelphia. Elsevier, pp 1526-1625.
39. Mahdi H, Schlick CJ, Kowk LL, ea al. 2013. Endometrial Cancer in Asian and American Indian/Alaskan Native Women: Tumor Characteristic, Treatment and Outcome Compared to Non-Hispanic White Women. Gynecologic Oncology. Vol 132, pp 443-9.
40. Ozbilen O, Sakarya DK, Bezircioglu I, et al. 2015. Comparison of Myometrial Invasion and Tumor Free Distance from Uterine Serosa in Endometrial Cancer. Asian Pacific Journal of Cancer Prevention. Vol 16(2), pp 519-22.



41. Zou S, Sun H, Fan L, et al. 2017. Prognostic Indicator in Patients with Early Stage Endometrioid Adenocarcinoma: A Retrospective Case-Control Study of 523 Patients. *International Journal of Clinical Expert Medical*. Vol 10(2), pp 3692-8.
42. Costas L, Frias-Gomez J, Guardiola M, et al. 2019. New Perspective in Screening and Early Detection of Endometrial Cancer. *International Journal of Cancer*. Vol 145, pp 3194-206.
43. Kluz T, Lozinski T, Czekierdowska S, et al. 2020. Tumor Budding Index and Microvessel Density Assessment in Patients with Endometrial Cancer: A Pilot Study. *Oncology Letters*. Vol 20, pp 2701-10.
44. Holcomb K, Dellatore R, Pedemonte B, et al. 2002. E-cadherin Expression in Endometrioid, Papillary, Serous and Clear Cell Carcinoma of the Endometrium. *The American College of Obstetrician and Gynecologist*. Vol 100(6), pp 1290-5.
45. Soliman N, Mohamed SA, Morsi DF. 2018. Expression of E-Cadherin, Her2/neu and P53 in Endometrial Carcinoma: Relation to Different Clinicopathological Predictors of the Prognosis. *Merit Research Journal of Medicine and Medical Sciences*. Vol. 6(11), pp. 407-15.
46. Cheng JC, Auersperg N, Leung PCK. 2011. Inhibition of p53 Represses E-cadherin Expression by Increasing DNA Methyltransferase-1 and Promoter Methylation in Serous Borderline Ovarian Tumor Cells. *Oncogene*. Vol. 30, pp. 3930-42.
47. Desai RA, Gao L, Raghavan S, et al. 2008. Cell Polarity Triggered by Cell-Cell Adhesion Via E-cadherin. *Journal of Cell Science*. Vol. 122, pp. 905-11.
48. De Smedt L, Palmans S, Sagaert X. 2015. Tumour budding in colorectal cancer: what do we know and what can we do? *Virchows Arch*.
49. Niwa Y, Yamada S, Koike M, et al. 2014. Epithelial to Mesenchymal Transition Correlates With Tumor Budding and Predicts Prognosis in Esophageal Squamous Cell Carcinoma. *Journal of Surgical Oncology*. Vol. 110, pp. 764-9.

50. Masugi Y, Yamazaki K, Hibi T, et al. 2010. Solitary Cell Infiltration is a Novel Indicator of Poor Prognosis and Epithelial-Mesenchymal Transition in Pancreatic Cancer. *Human Pathology*. Vol 41, pp. 1061–8.
51. Attramadal CG, Kumar S, Boysen ME, et al. 2015. Tumor Budding, EMT and Cancer Stem Cells in T1-2/N0 Oral Squamous Cell Carcinomas. *Anticancer Research*. Vol 35, Pp 6111-20.
52. Bronsert P, Enderle-Ammour K, Bader M, et al. 2014. Cancer Cell Invasion and EMT Marker Expression - a Three-Dimensional Study of the Human Cancer-Host Interface. *Journal of Pathology*. Vol. 234, Pp 410–22.

